CatSci, a provider of innovative process research and development services to emerging, mid-sized and large pharma worldwide, will be exhibiting on booth 9J40 at CPhI Worldwide in Madrid, Spain, October 9-11 2018. CatSci has also been shortlisted as a finalist at the annual CPhI Pharma Awards in the prestigious Excellence in Pharma: Contract Services and Outsourcing category.

CatSci provides innovative process research and development services to emerging, mid-sized and large pharma. CatSci proudly serves customers across the globe from late-stage lead optimisation through to launch. As an independent, scientifically-unbiased and commercially-minded CRO, CatSci is dedicated to understanding and optimising their clients’ chemical reactions and processes. Favouring a consultative approach, they take the time to understand their clients’ project objectives and then resolve the challenges that they face efficiently and effectively.

Non-GMP material supply from milligrams to kilograms is conveniently carried out in CatSci’s laboratory, whilst for larger quantities and/or GMP manufacture, they are able to work with trusted partners or their clients’ preferred suppliers.

Representatives from CatSci will be available during CPhI Worldwide to discuss the company’s latest news and developments. For example, Dr. Ross Burn, CEO, completed a MSci in Forensic and Analytical Chemistry at the University of Strathclyde, Glasgow. He completed his PhD in 2007 on the use of chromatography, electrophoresis and mass spectrometry for mining the human plasma proteome for biomarkers of disease with Prof. David Perrett at Barts and the London, Queen Mary’s School of Medicine, University of London. In 2007, he joined AstraZeneca as an Analytical Chemist to support the AstraZeneca Catalysis Facility and develop techniques to improve process understanding.